CureVac N.V. (5CV.F)
Frankfurt - Frankfurt Delayed Price. Currency in EUR
Add to watchlist
At close: 04:17PM CEST
| Previous Close | 2.6580 |
| Open | 2.6000 |
| Bid | 2.6040 x N/A |
| Ask | 2.6540 x N/A |
| Day's Range | 2.6000 - 2.6920 |
| 52 Week Range | 2.0560 - 5.7500 |
| Volume | |
| Avg. Volume | 15,031 |
| Market Cap | 591.292M |
| Beta (5Y Monthly) | 2.61 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.2500 |
| Earnings Date | Nov 12, 2024 - Nov 18, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 72.97 |
ReutersPfizer, BioNTech win bid to invalidate CureVac's UK COVID vaccine patents
LONDON (Reuters) -Pfizer and its German partner BioNTech on Tuesday won their attempt to invalidate two of rival CureVac's patents at London's High Court. Pfizer and BioNTech had filed their lawsuit in September 2022 over patents relating to messenger RNA (mRNA) technology, which underpins Pfizer and BioNTech's COVID-19 vaccine.
Simply Wall St.CureVac N.V.'s (NASDAQ:CVAC) top owners are individual investors with 35% stake, while 31% is held by private equity firms
Key Insights CureVac's significant individual investors ownership suggests that the key decisions are influenced by...
ACCESSWIRECureVac's CVGBM Cancer Vaccine Induces Promising Immune Responses in Phase 1 Study in Glioblastoma Presented at the ESMO 2024 Congress
Preliminary immunogenicity results demonstrate induction of cancer antigen-specific T-cell responses in 77% of evaluable patients following CVGBM monotherapy 84% of immune responses were de novo, observed in patients without pre-existingT-cell activity ...
© 2024 Yahoo. All rights reserved.